The Latest Cardiac and Vascular News
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE™ Therapy, using the Revivent TC™ Transcatheter Ventricular Enhancement System. The […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company’s board of directors. Mr. Cohen, an accredited public company director, has nearly 40 years of experience leading […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that it has been named by FierceMedTech as one of the “Fierce 15” for 2019, designating it as one of the most promising private medtech companies in the […]
REVIVE-HF seeks to demonstrate superiority of the Revivent TC System to current guideline treatment for heart failure SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New York’s Mount Sinai Health System has signed on to the pivotal ALIVE Trial of the Revivent TC™ TransCatheter Ventricular Enhancement System as co-principal investigator. Dr. Stone […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the highest priority reimbursement in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System by achieving the NUB Status 1 designation from InEk, the German […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced the extension of its CE Mark for the Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure to May 2024. “The extension of our CE Mark is not only an important […]
Study Published in European Journal of Heart Failure Shows Significant and Sustained Improvement in Heart Function, Symptom Relief and Quality of Life Using Less Invasive Left Ventricular Enhancement Device SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling, today announced online publication of positive […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately-held company with a first-in-class, transcatheter-based structural heart device to treat heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation status for its Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure. Less Invasive […]
SAN RAMON, Calif., Oct. 8, 2019 /PRNewswire/ — BioVentrix, Inc. announced the first patient was enrolled and treated in the REVIVE-HF European study, a prospective multi-center, dual-arm randomized controlled study evaluating the treatment of ischemic cardiomyopathy induced heart failure with the Revivent TCTM System compared to Guideline-Directed Medical Therapy (GDMT) or drug treatment. The patient […]
